NEWS HIGHLIGHTSMedia Articles Related to Sprycel (Dasatinib)
FDA Approved Leukemia Drug Shows Promising Activity In Ovarian Cancer Cells
Source: Lymphoma / Leukemia / Myeloma News From Medical News Today [2009.11.11]
The drug Sprycel, approved for use by the U.S. Food and Drug Administration in patients with chronic myeloid leukemia, significantly inhibited the growth and invasiveness of ovarian cancer cells and also promoted their death, a study by researchers with UCLA's Jonsson Comprehensive Cancer Center found.
Genentech And Biogen Idec Receive A Complete Response From The FDA For Rituxan For Chronic Lymphocytic Leukemia
Source: Health News from Medical News Today [2009.11.19]
Genentech, Inc., a wholly-owned member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), and Biogen Idec (Nasdaq: BIIB) announced today that the U.S.
Finding May Give Hope To More Leukemia Patients So They May Live Cancer-Free
Source: Lymphoma / Leukemia / Myeloma News From Medical News Today [2009.11.16]
A new study from the Masonic Cancer Center, University of Minnesota shows that patients who have acute leukemia and are transplanted with two units of umbilical cord blood (UCB) have significantly reduced risk of the disease returning. This finding has the potential to change the current medical practice of using one unit of UCB for treatment of patients who are at high risk for recurrence of leukemia and other cancers of the blood and bone marrow. Michael Verneris, M.D.
Leukemia Drug May Help Some Ovarian Cancer Patients (HealthDay)
Source: Y! Health News Search RSS Feed [2009.11.12]
HealthDay - THURSDAY, Nov. 12 (HealthDay News) -- A drug for people with a form of
leukemia holds promise as a possible treatment for ovarian cancer, new
research suggests.
Leukemia Drug May Help Some Ovarian Cancer Patients
Source: MedicineNet Leukemia Specialty [2009.11.12]
Title: Leukemia Drug May Help Some Ovarian Cancer Patients
Category: Health News
Created: 11/12/2009 8:10:00 AM
Last Editorial Review: 11/12/2009
Published Studies Related to Sprycel (Dasatinib)
Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: two-year follow-up of a randomized phase 2 study (START-R). [2009.09.15]
BACKGROUND: In patients with chronic-phase chronic myeloid leukemia (CP-CML), imatinib resistance is of increasing importance. Imatinib dose escalation was the main treatment option before dasatinib, which has 325-fold more potent inhibition than imatinib against unmutated Bcr-Abl in vitro. Data with a minimum of 2 years of follow-up were available for the current study of dasatinib and high-dose imatinib in CP-CML resistant to imatinib at daily doses from 400 mg to 600 mg... CONCLUSIONS: After 2 years of follow-up, dasatinib demonstrated durable responses and improved response and progression-free survival rates relative to high-dose imatinib. Copyright (c) 2009 American Cancer Society.
Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up. [2009.06.18]
Dasatinib is the most potent BCR-ABL inhibitor, with 325-fold higher potency than imatinib against unmutated BCR-ABL in vitro. Studies have demonstrated the benefits of dasatinib 70 mg twice daily in patients with accelerated-phase chronic myeloid leukemia intolerant or resistant to imatinib... This trial is registered at www.clinicaltrials.gov as #CA180-035.
Phase I study of the effect of gastric acid pH modulators on the bioavailability of oral dasatinib in healthy subjects. [2009.06]
Dasatinib is a tyrosine kinase inhibitor (including BCR-ABL and the SRC family) that is effective in patients with chronic myeloid leukemia... Dasatinib may be administered with acid-neutralizing antacids if the doses are temporally separated by at least 2 hours.
Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial. [2007.06.15]
Therapeutic options for chronic myelogenous leukemia (CML) resistant to 400 to 600 mg imatinib are limited... Dasatinib represents a safe and effective therapy for CP-CML resistant to conventional imatinib doses with improved cytogenetic and molecular response rates and progression-free survival relative to high-dose imatinib.
Flow cytometric determination of Src phosphorylation in pediatric patients treated with dasatinib. [2009.12]
Tyrosine kinase inhibitors, such as imatinib, have dramatically improved the outcomes for patients with selected cancers. For imatinib, western blotting of phospho-CrkL was an insensitive, indirect, and descriptive method to determine drug efficacy...
Clinical Trials Related to Sprycel (Dasatinib)
Phase II Study Evaluating The Safety And Response To Neoadjuvant Dasatinib In Early Stage Non-Small Cell Lung Cancer [Recruiting]
Src expression has been identified in a majority of NSCLC cell lines and there is preclinical
evidence that Src family kinases may be important in hypoxic growth and angiogenesis in
NSCLC. We hypothesize that the inhibition of Src pathway with dasatinib will demonstrate
anti-tumor activity in early stage NSCLC, with a tolerable safety profile.
Patients will receive dasatinib, a Src inhibitor, for 3 weeks prior to surgical resection for
early stage NSCLC. Fresh frozen tumor tissue is needed for genomic analysis. If fresh frozen
tumor tissue is not available from the initial diagnosis, a biopsy will be required to
participate in this trial. A second tumor sample will be obtained at time of surgical
resection to evaluate for changes in genomic expression profiles.
Patients will be eligible to receive 3 months of adjuvant dasatinib therapy after completion
of standard adjuvant therapy or after recovery from surgery if no standard adjuvant therapy
is given, if there is evidence of neoadjuvant tumor response (radiologic and/or pathologic)
to dasatinib.
Many patients who present with NSCLC are active smokers. Patients who are smoking up until
the time of their surgery experience increased peri-operative complications compared to
patients who have not smoked cigarettes immediately prior to surgery. While this trial will
not be limited to active smokers, the period of smoking cessation prior to surgery is an
attractive window of opportunity during which the potentially active novel anticancer therapy
dasatinib can be offered to the patient.
Randomized Phase II Trial of Letrozole With or Without Dasatinib as First and Second-line Treatment for Hormone Receptor-positive, HER2-negative Post-menopausal Breast Cancer That is Unresectable, Locally Recurrent or Metastatic [Recruiting]
The purpose of this study is to find out what effect the combination of letrozole (brand
name: Femara) and dasatinib (brand name: Sprycel) has on metastatic breast cancer compared
to letrozole alone
Ph I Dasatinib + Erlotinib in Recurrent MG [Recruiting]
Primary:
To determine maximum tolerated dose & dose limiting toxicity of dasatinib when combined w
erlotinib among pts w recurrent MG
Secondary:
To further evaluate safety & tolerability of dasatinib + erlotinib To evaluate
pharmacokinetics of dasatinib when administered w erlotinib among recurrent MG pts who are
on & not on CYP-3A enzyme inducing anti-epileptic drugs To evaluate for anti-tumor activity
with this regimen in this patient population
Efficacy and Safety Study of Dasatinib in Patients With Chronic Myeloid Leukemia [Not yet recruiting]
This is a phase II efficacy (indicates the capacity for beneficial change or therapeutic
effect) and safety study of Dasatinib in patients with relapsed Chronic Myeloid Leukemia
(CML) following a Stem Cell Transplant (SCT) and who are not benefiting from other
treatment, such as imatinib therapy.
A relapse is when an illness that has seemed to be getting better, or to have been cured,
comes back or gets worse again.
A total of 50 patients ≥18 years of age will be registered on the trial.
Safety Study Of Cetuximab Plus Dasatinib (BMS-354825) in Treating Advanced Solid Malignancies [Recruiting]
This is an open-label, safety study of cetuximab and differing dose levels of dasatinib in
adult patients with advanced solid malignancies. Cetuximab will be administered as an
intravenous infusion weekly. Dasatinib will be taken orally, once a day, on a continuous
schedule at differing dose levels. The primary objective of this study is to determine the
toxicities and the maximum tolerated doses of dasatinib when combined with cetuximab for the
treatment of advanced solid tumors.
|
